Liz Wilcox (S46) Liz, we have a mushroom Swiss burger too. And tbh it’s better. We’d love to send you a gift from us so you and your daughter can start a new tradition. 😉

SCIENTIFIC PRESENTATIONS (downloadable poster) at
cardiffoncology.com/scientific-pre…

Congratulations!

#CRCSM

Nordic ORgan Preservation Pilot Approach Nonrandomised Single-Arm Trial for Non-Operative Management of Rectal Cancer (NORPPA-1)

200 patients
ESTONIA
FINLAND
PI: Toni T Seppälä

NCT06328361

ARC-9: Phase Ib/II study to evaluate etrumadenant (AB928)-based treatment combinations in patients with metastatic colorectal cancer abstract TPS150 #GI21 Colorectal Cancer Alliance The encouraging results from ARC-3 warrant further evaluation of etrumadenant-based combination therapy for mCRC

Latest from #ASCOPlenarySeries : Glecirasib Shows Promise in Treating Patients w/ #NSCLC w/ KRAS G12C Mutation

📅 Live presentation tomorrow, 4/30, at 3 PM ET
Panel: Drs. Melissa L. Johnson, Yuankai Shi, Stephen V Liu, MD, Julia Rotow MD

Abstract: brnw.ch/21wJiEh #LCSM @oncoalert

Newly published article highlights a promising KRAS G12C targeted therapy for advanced NSCLC, offering potential advancements in treatment options. Valuable read for #OncTwitter . bit.ly/3UkLT9S

The best ASCO is a curated #ASCO24

#crcsm
Kai-Keen Shiu

Cannabis in patients with cancer. For someone like me, working in a state (MN) where medical cannabis is legal and often used and requested, this is a helpful reference. Much better data are needed and I hope to see well-designed trials soon. Journal of Clinical Oncology

ascopubs.org/doi/full/10.12…

Navigating stage IV (metastatic) #ColorectalCancer treatment can be overwhelming. Join Dr. Cathy Eng and Phuong Gallagher as they discuss stage IV #ColorectalCancer and answer your questions!

fightcrc.zoom.us/webinar/regist…

Definitely a group with insight, that grows more and more important as patient advocacy needs become greater.

Together, we can move the dial, push the (right buttons), come up with out of the box solutions, learn from each other's playbook, find and share our own voices

Level 1: Relaxed Goose
Level 2: Slightly Miffed Goose
Level 3: Quite Cross Goose
Level 4: Livid Goose
Level 5: Violent Goose

The #mRNA -4359 #ClinicalTrial is set to recruit patients globally over the next three years. Each #patient will be closely monitored for up to 34 months after treatment. These trials represent a significant leap to transforming #cancer treatments. #Sitero livescience.com/health/cancer/…

“I’m an advocate because I’m angry” said Simone Ledward-Boseman, during her visit at Dana-Farber to continue to spread awareness on young-onset colorectal cancer and connect with survivors and caregivers at the YOCCC 5th Annual Patient and Family forum.
blog.dana-farber.org/insight/2024/0…

#Roche 's Oncology in Q1 2024

Significant changes have occurred in early-stage oncology assets. In February, Repare announced the return of the rights to camonsertib (an ATR inhibitor). Additionally, Roche, which acquired belvarafenib (a pan-Raf inhibitor) from Hanmi Pharma, has…

Study of IK-595 in RAS- or RAF-altered Advanced Tumors

NCT06270082 - FIH trial opened Dec 2023
#KRAS #BRAF #NRAS

💊 A new study by David Church, PhD, of Nuffield Department of Medicine sought to determine the prognostic value of the Immunoscore assay in patients with stage 3 #colorectalcancer who received FOLFOX or CAPOX.

👉 Learn more about the assay's prognostic value: buff.ly/3vS56r8

#ColonCancer